GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Board Meeting Intimation for Audited Financial Results (Standalone & Consolidated) For The Year Ended 31St March 2026 And Dividend If Any
GlaxoSmithKline Pharmaceuticals board will convene on May 13, 2026. The meeting will focus on approving the audited financial results for Q4 FY26 and the full financial year, and considering a dividend recommendation.
Apr 22 2026 12:04:00
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals' Board authorized key personnel to determine the materiality of any event or transaction for stock exchange disclosures. This ensures compliance with SEBI Regulation 30(5). The authorized individuals include the Managing Director, CFO, Company Secretary, and Head of Legal.
Apr 21 2026 11:04:00
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals appointed Vinay Subramanian as Commercial Head - Oncology. He brings over 24 years of experience from various sectors like Pharmaceuticals and Life Science, previously holding leadership roles at Roche and GE Healthcare.
Apr 21 2026 11:04:00
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline's board approved the appointment of Mr. Ronojit Biswas as Executive Director for a 36-month term, effective April 1, 2026. This appointment leverages his 25 years of experience with GSK across various international markets and leadership roles.
Apr 21 2026 10:04:00
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals appointed Mr. Vinay Subramanian, Commercial Head – Oncology, to its leadership team, effective April 20, 2026. He has over 24 years of experience in pharmaceuticals and healthcare.
Apr 21 2026 10:04:00
GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Announcement under Regulation 30 (LODR)-Change in Management
GlaxoSmithKline Pharmaceuticals Limited (GSK) appoints Mr. Vinay Subramanian, Commercial Head – Oncology, to its leadership team as Senior Management Personnel, effective April 20, 2026. Subramanian has over 24 years of experience in pharma and healthcare, previously with Roche and GE Healthcare.
Apr 21 2026 10:04:00
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline shareholders have approved the appointments of Mr. Ronojit Biswas as a Director and as Whole-time Director & CFO via postal ballot. Both resolutions passed with over 99% of votes cast in favor, with results announced on April 8, 2026.
Apr 08 2026 23:04:00
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline shareholders have approved the appointments of Mr. Ronojit Biswas as a Director and as Whole-time Director & CFO via postal ballot. Both resolutions passed with over 99% of votes cast in favor, with results announced on April 8, 2026.
Apr 08 2026 23:04:00
GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
GlaxoSmithKline Pharma shareholders approved the appointment of Mr. Ronojit Biswas as Director and Whole-time Director & CFO through postal ballot. Both resolutions received strong support, passing with over 99% of valid votes in favour.
Apr 08 2026 23:04:00
GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
GlaxoSmithKline Pharma shareholders approved the appointment of Mr. Ronojit Biswas as Director and Whole-time Director & CFO through postal ballot. Both resolutions received strong support, passing with over 99% of valid votes in favour.
Apr 08 2026 23:04:00
Read More